Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Aug;69(4):343–355. doi: 10.1016/j.curtheres.2008.08.002

Effect of cartilage oligomeric matrix protein angiopoietin-1 on peripheral nerves in db/db diabetic mice

Heung Yong Jin 1, Ming Han Piao 1, Ji Hyun Park 1, Hong Sun Baek 1, Sik Lee 2, Won Kim 2, Sung Kwang Park 2, Chong Hwa Kim 3, Gou Young Koh 4, Tae Sun Park 1,*
PMCID: PMC3969925  PMID: 24692811

Abstract

Background: Vascular and inflammatory processes have been reported to be factors in the pathogenesis of diabetic neuropathy. Angiopoietin-1 (Ang1) plays essential roles in regulating vascular growth, development, maturation, permeability, and inflammation.

Objective: The aim of this study was to investigate the effect of cartilage oligomeric matrix protein (COMP)-Ang1, which is a soluble, stable, potent Ang1 variant, on peripheral nerves in db/db diabetic mice.

Methods: The db/db diabetic mice were randomized into 2 groups based on their weight and glucose level and treated with recombinant adenovirus (Ade), expressing either COMP-Ang1 or the β-galactosidase gene (LacZ) (control), for 8 weeks. Immunohistochemistry was performed using a polyclonal antibody of antiprotein gene product and a secondary antibody. Intraepidermal nerve fiber density (IENFD) was quantified as nerve fiber abundance per unit length of epidermis (IENF/mm). In addition, the total capillary length (TCL) per unit length of epidermis was summed (mm/mm2). All slides were coded and the capillary length and the number of nerve fibers were calculated by a blinded observer.

Results: Ten diabetic db/db mice (mean [SD] weight, 38.7 [1.95] g) were randomized to receive Ade-COMP-Ang1 or Ade-LacZ. IENFD was significantly greater in the Ade-COMP-Ang1 group compared with the Ade-LacZ group (mean [SD] 8.95 [3.30] vs 3.57 [0.73]/mm; P < 0.05). TCL was also significantly greater in the Ade-COMP-Ang1 group (2.79 [0.99] vs 2.04 [0.58] mm/mm2; P < 0.05). Compared with baseline, fasting blood glucose concentration after 8 weeks of treatment decreased significantly more in the Ade-COMP-Ang1 group than in the Ade-LacZ group (489 [45] to 361 [81] vs 495 [48] to 521 [70] mg/dL; P < 0.05).

Conclusions: These results suggest that Ade-COMP-Ang1 might have had proliferative effects on peripheral nerve and cutaneous capillaries in this small animal study. Further investigation of the metabolic effect, target site, and related mediator of COMP-Ang1 is needed.

Key words: COMP-angiopoietin-1, db/db diabetic mice, peripheral neuropathy

Full Text

The Full Text of this article is available as a PDF (762.5 KB).

References

  • 1.Boulton AJ. The diabetic foot: From art to science: The 18th Camillo Golgi lecture. Diabetologia. 2004;47:1343–1353. doi: 10.1007/s00125-004-1463-y. [DOI] [PubMed] [Google Scholar]
  • 2.The Diabetes Control and Complications Trial Research Group The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–568. doi: 10.7326/0003-4819-122-8-199504150-00001. [DOI] [PubMed] [Google Scholar]
  • 3.Tesfaye S, Stevens LK, Stephenson JM. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377–1384. doi: 10.1007/s001250050586. [DOI] [PubMed] [Google Scholar]
  • 4.Wang Y, Schmeichel AM, Iida H. Enhanced inflammatory response via activation of NF-kappaβ in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci. 2006;247:47–52. doi: 10.1016/j.jns.2006.03.011. [DOI] [PubMed] [Google Scholar]
  • 5.Goss JR, Goins WF, Lacomis D. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes. 2002;51:2227–2232. doi: 10.2337/diabetes.51.7.2227. [DOI] [PubMed] [Google Scholar]
  • 6.Suri C, McClain J, Thurston G. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282:468–471. doi: 10.1126/science.282.5388.468. [DOI] [PubMed] [Google Scholar]
  • 7.Cho CH, Kammerer RA, Lee HJ. COMP-Angl: A designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci U S A. 2004;101:5547–5552. doi: 10.1073/pnas.0307574101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cho CH, Kammerer RA, Lee HJ. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101:5553–5558. doi: 10.1073/pnas.0307575101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cho CH, Kim KE, Byun J. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res. Circ Res. 2005;2006;898:86–94. e69. doi: 10.1161/01.RES.0000174093.64855.a6. [published correction appears in. ] [DOI] [PubMed] [Google Scholar]
  • 10.Lee S, Kim W, Moon SO. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant. 2007;22:396–408. doi: 10.1093/ndt/gfl598. [DOI] [PubMed] [Google Scholar]
  • 11.Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43:957–973. doi: 10.1007/s001250051477. [DOI] [PubMed] [Google Scholar]
  • 12.Boulton AJ, Vinik AI, Arezzo JC, American Diabetes Association Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962. doi: 10.2337/diacare.28.4.956. [DOI] [PubMed] [Google Scholar]
  • 13.Siemionow M, Demir Y. Diabetic neuropathy: Pathogenesis and treatment. J Reconstr Microsurg. 2004;20:241–252. doi: 10.1055/s-2004-823112. [DOI] [PubMed] [Google Scholar]
  • 14.Dyck PJ, Davies JL, Wilson DM. Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999;22:1479–1486. doi: 10.2337/diacare.22.9.1479. [DOI] [PubMed] [Google Scholar]
  • 15.Dyck PJ, Zimmerman BR, Vilen TH. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med. 1988;319:542–548. doi: 10.1056/NEJM198809013190904. [DOI] [PubMed] [Google Scholar]
  • 16.Nishikawa T, Edelstein D, Du XL. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790. doi: 10.1038/35008121. [DOI] [PubMed] [Google Scholar]
  • 17.The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 18.Tomlinson DR, Willars GB, Carrington AL. Aldose reductase inhibitors and diabetic complications. Pharmacol Ther. 1992;54:151–194. doi: 10.1016/0163-7258(92)90031-t. [DOI] [PubMed] [Google Scholar]
  • 19.Yagihashi S, Kamijo M, Baba M. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 1992;41:47–52. doi: 10.2337/diab.41.1.47. [DOI] [PubMed] [Google Scholar]
  • 20.Nakamura J, Kato K, Hamada Y. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999;48:2090–2095. doi: 10.2337/diabetes.48.10.2090. [DOI] [PubMed] [Google Scholar]
  • 21.Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004;25:612–628. doi: 10.1210/er.2003-0019. [DOI] [PubMed] [Google Scholar]
  • 22.Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats: Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest. 1995;96:1159–1163. doi: 10.1172/JCI118104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Suri C, Jones PF, Patan S. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–1180. doi: 10.1016/s0092-8674(00)81813-9. [DOI] [PubMed] [Google Scholar]
  • 24.Schmelzer JD, Zochodne DW, Low PA. Ischemic and reperfusion injury of rat peripheral nerve. Proc Natl Acad Sci U S A. 1989;86:1639–1642. doi: 10.1073/pnas.86.5.1639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kurose I, Granger DN. Evidence implicating xanthine oxidase and neutrophils in reperfusion-induced microvascular dysfunction. Ann N Y Acad Sci. 1994;723:158–179. [PubMed] [Google Scholar]
  • 26.Kim W, Moon SO, Lee SY. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol. 2006;17:2474–2483. doi: 10.1681/ASN.2006020109. [DOI] [PubMed] [Google Scholar]
  • 27.Kim I, Moon SO, Park SK. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Cin Res. 2001;89:477–479. doi: 10.1161/hh1801.097034. [DOI] [PubMed] [Google Scholar]
  • 28.Nakae M, Kamiya H, Naruse K. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes. 2006;55:1470–1477. doi: 10.2337/db05-1160. [DOI] [PubMed] [Google Scholar]
  • 29.Schratzberger P, Walter DH, Rittig K. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest. 2001;107:1083–1092. doi: 10.1172/JCI12188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kato N, Nemoto K, Nakanishi K. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes. 2005;54:846–854. doi: 10.2337/diabetes.54.3.846. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES